Patients with OPRM1 A/A genotype and patients with COMT Met/Met genotype have been invariably associated with a more favorable phenotype, also in specific cancer patients’ populations: less pain sensitivity, better response to opioids with lower consumption, less side effects [35,36,39,66]. Here, OPRM1 is linked to cancer.